



Your views needed

The National Institute for Health and Care Excellence (NICE) will be appraising a treatment called **risankizumab for treating moderate to severe plaque psoriasis** in May 2019.

The treatment is classed as a systemic biologic agent, given as a self-administered subcutaneous injection.

The proposed use of the treatment will probably be at the same point in the psoriasis treatment pathway as other similar treatments which include: adalimumab, etanercept, ustekinumab, ixekizumab, brodalumab, guselkumab and infiximab.

To learn more and to give your views [go to the survey](#).



Invitation to parents of children with psoriasis

A group of researchers based at The University of Sheffield (U.K), would like to invite parents of children with psoriasis to take part in a free 9-week mindfulness course. The course is designed to reduce stress and improve well-being.

They are looking for individuals **who live in the South Yorkshire area**, as all mindfulness sessions will take place in the centre of Sheffield.

Each session will last for approximately 3 hours. Participants will be asked to complete some questionnaires before, during, and after the course. They would also like to interview participants at the end of the course about their experiences.

[For full details visit our website.](#)

Contact Us

Mailing address:
PAPAA
3 Horseshoe Business Park
Lye Lane
Bricket Wood
St Albans
AL2 3TA

01923 672837
info@papaa.org

Connect With Us



Donate Online

